

# Gaia Griguolo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6598164/publications.pdf>

Version: 2024-02-01

111  
papers

1,700  
citations

304743

22  
h-index

345221

36  
g-index

114  
all docs

114  
docs citations

114  
times ranked

2180  
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial. <i>Clinical Cancer Research</i> , 2022, 28, 308-317.	7.0	36
2	Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer. <i>EBioMedicine</i> , 2022, 75, 103801.	6.1	47
3	Abstract P2-12-04: Characterization of gut microbiome composition in triple negative breast cancer patients treated with neoadjuvant chemotherapy. <i>Cancer Research</i> , 2022, 82, P2-12-04-P2-12-04.	0.9	0
4	Abstract PD4-01: Response according to revised RANO criteria is associated with overall survival in breast cancer patients with leptomeningeal metastasis. <i>Cancer Research</i> , 2022, 82, PD4-01-PD4-01.	0.9	0
5	Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival. <i>ESMO Open</i> , 2022, 7, 100409.	4.5	25
6	Survival after neoadjuvant therapy with trastuzumab+lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials. <i>ESMO Open</i> , 2022, 7, 100433.	4.5	24
7	Gastric metastases of breast cancer: Histopathological and molecular characterization of a single Institution case series. <i>Pathology Research and Practice</i> , 2022, 233, 153872.	2.3	1
8	Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review. <i>Cancers</i> , 2022, 14, 1898.	3.7	20
9	HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment. <i>Npj Breast Cancer</i> , 2022, 8, .	5.2	46
10	A comprehensive profiling of the immune microenvironment of breast cancer brain metastases. <i>Neuro-Oncology</i> , 2022, 24, 2146-2158.	1.2	9
11	Abstract PS5-14: Gene-expression profiling and response to neoadjuvant endocrine treatment in the phase II LETLOB trial. , 2021, , .		1
12	Abstract PS10-02: A good prognosis of endocrine-dependent tumors among residual invasive cancer after anti-HER2 therapy: CALGB 40601 (Alliance) and validation studies. , 2021, , .		0
13	Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 3116-3125.	7.0	9
14	Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 12.	5.2	9
15	Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer. <i>Npj Precision Oncology</i> , 2021, 5, 23.	5.4	26
16	ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 625636.	2.8	8
17	Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET). <i>Clinical Cancer Research</i> , 2021, 27, 3443-3455.	7.0	4
18	T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study. <i>ESMO Open</i> , 2021, 6, 100099.	4.5	12

#	ARTICLE	IF	CITATIONS
19	4MO_PR HER2-low breast cancer: Evolution from primary breast cancer to relapse. <i>Annals of Oncology</i> , 2021, 32, S23.	1.2	1
20	122P Abemaciclib in HR+/HER2- metastatic breast cancer: A real-world experience. <i>Annals of Oncology</i> , 2021, 32, S73-S74.	1.2	1
21	Profiling of immune checkpoint biomarkers by multiplex immunofluorescence in breast cancer brain metastases. <i>Journal of Clinical Oncology</i> , 2021, 39, 2021-2021.	1.6	5
22	Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer. <i>Cancer Treatment Reviews</i> , 2021, 98, 102222.	7.7	21
23	Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial. <i>European Journal of Cancer</i> , 2021, 153, 133-141.	2.8	20
24	Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy. <i>Npj Breast Cancer</i> , 2021, 7, 101.	5.2	44
25	117O Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: A meta-analysis of randomised trials. <i>Annals of Oncology</i> , 2021, 32, S407.	1.2	7
26	212P HER2-low breast cancer: Evolution from primary tumor to residual disease after neoadjuvant treatment. <i>Annals of Oncology</i> , 2021, 32, S451.	1.2	0
27	103P Rate of BRCA1/2 pathogenic variants according to family and personal history of cancer in a large cohort of triple-negative breast cancer (TNBC) patients (pts) younger than 60 years of age. <i>Annals of Oncology</i> , 2021, 32, S400-S401.	1.2	1
28	129P Integration of gene expression and tumor-infiltrating lymphocytes (TILs) to predict pCR after neoadjuvant chemotherapy and nivolumab for patients with luminal B-like breast cancer in the phase II GIADA trial. <i>Annals of Oncology</i> , 2021, 32, S414.	1.2	1
29	281P Prognostic impact of immune interactions in HER2+ and triple-negative breast cancer brain metastases. <i>Annals of Oncology</i> , 2021, 32, S486-S487.	1.2	0
30	Locoregional and Locally Advanced Breast Cancer. <i>UNIPA Springer Series</i> , 2021, , 429-466.	0.1	0
31	Evolution of HER2-low expression from primary to recurrent breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 137.	5.2	94
32	Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2- breast cancer: Available Evidence and Clinical Implications. <i>Cancer Treatment Reviews</i> , 2021, 102, 102323.	7.7	17
33	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. <i>Journal of the National Cancer Institute</i> , 2020, 112, 46-54.	6.3	97
34	Use of Electronic Administrative Databases to Measure Quality Indicators of Breast Cancer Care: Experience of Five Regional Oncology Networks in Italy. <i>JCO Oncology Practice</i> , 2020, 16, e211-e220.	2.9	11
35	Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective study. <i>Breast Journal</i> , 2020, 26, 1296-1301.	1.0	13
36	8P Characterization of immune microenvironment before and following anti-HER2 neoadjuvant therapy (NAT). <i>Annals of Oncology</i> , 2020, 31, S19.	1.2	1

#	ARTICLE	IF	CITATIONS
37	4P Independent validation of the PAM50-based chemoendocrine score (CES) as pathologic complete response (pCR) and disease-free survival (DFS) predictor in hormone receptor (HR)+/HER2+ breast cancer (BC). <i>Annals of Oncology</i> , 2020, 31, S17.	1.2	1
38	Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer. <i>Oncologist</i> , 2020, 25, e1355-e1362.	3.7	8
39	ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer. <i>Cancers</i> , 2020, 12, 1902.	3.7	29
40	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. <i>Lancet Oncology</i> , The, 2020, 21, 1455-1464.	10.7	52
41	The Tumor Microenvironment of Primitive and Metastatic Breast Cancer: Implications for Novel Therapeutic Strategies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8102.	4.1	24
42	<i>PIK3CA</i> Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. <i>Clinical Cancer Research</i> , 2020, 26, 5843-5851.	7.0	17
43	99P Association of gut microbiome diversity and composition with pathological complete response (pCR) after neoadjuvant chemotherapy in triple negative breast cancer. <i>Annals of Oncology</i> , 2020, 31, S50.	1.2	0
44	Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors. <i>Cancer Treatment Reviews</i> , 2020, 88, 102064.	7.7	41
45	168P Development of a combined clinical model to predict progression-free survival (PFS) in advanced breast cancer (ABC) treated with CDK4/6 inhibitors (CDK4/6i). <i>Annals of Oncology</i> , 2020, 31, S76.	1.2	0
46	Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy. <i>European Journal of Cancer</i> , 2020, 136, 7-15.	2.8	32
47	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2020, 84, 101965.	7.7	92
48	Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. <i>Nature Communications</i> , 2020, 11, 385.	12.8	67
49	Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model. <i>Breast</i> , 2020, 50, 56-63.	2.2	4
50	Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 582-582.	1.6	2
51	Olaparib for advanced breast cancer. <i>Future Oncology</i> , 2020, 16, 717-732.	2.4	8
52	Abstract P5-06-14: Integrating CD8, FOXP3 and PD-L1 expression in prognostic models for triple negative breast cancer (TNBC): An analysis of 265 patients treated with standard therapy for stage I-III disease. , 2020, , .		0
53	Abstract P5-06-12: Validation of residual proliferative cancer burden (RPCB) as a predictor of long-term outcome following neoadjuvant chemotherapy in hormone-receptor positive/HER2 negative breast cancer patients. , 2020, , .		0
54	Immune microenvironment profiling of breast cancer brain metastases using multiplex immunofluorescence.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2526-2526.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Abstract P3-08-05: Impact of estrogen receptor levels on outcome in triple negative breast cancer patients treated with (neo)adjuvant chemotherapy. , 2020, , .		0
56	Patterns of Fertility Preservation and Pregnancy Outcome After Breast Cancer at a Large Comprehensive Cancer Center. <i>Journal of Women's Health</i> , 2019, 28, 544-550.	3.3	9
57	BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis. <i>Breast</i> , 2019, 47, 77-84.	2.2	19
58	Carboplatin-containing neoadjuvant chemotherapy for triple negative breast cancer (TNBC): A propensity score-matched study. <i>Annals of Oncology</i> , 2019, 30, v64-v65.	1.2	0
59	Immune infiltrate composition across intrinsic subtypes in hormone receptor (HR)+/HER2- early breast cancer (BC) enrolled in the prospective LETLOB trial. <i>Annals of Oncology</i> , 2019, 30, v81.	1.2	2
60	PAM50 HER2-enriched subtype and pathological complete response in HER2-positive early breast cancer: A meta-analysis. <i>Annals of Oncology</i> , 2019, 30, v82.	1.2	1
61	Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value. <i>Oncologist</i> , 2019, 24, e1055-e1069.	3.7	36
62	ERBB2 mRNA as predictor of response to anti-HER2 antibody-drug conjugates (ADC) in breast cancer (BC). <i>Annals of Oncology</i> , 2019, 30, iii7.	1.2	2
63	Androgen Receptor Expression and Association With Distant Disease-Free Survival in Triple Negative Breast Cancer: Analysis of 263 Patients Treated With Standard Therapy for Stage I-III Disease. <i>Frontiers in Oncology</i> , 2019, 9, 452.	2.8	43
64	Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer. , 2019, 7, 90.		80
65	De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study. <i>Annals of Oncology</i> , 2019, 30, 921-926.	1.2	64
66	Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial. <i>BMC Medicine</i> , 2019, 17, 207.	5.5	4
67	Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1â€“T3, N0â€“N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study. <i>Oncologist</i> , 2019, 24, 1424-1431.	3.7	22
68	PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+ breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 544-544.	1.6	6
69	On-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome.. <i>Journal of Clinical Oncology</i> , 2019, 37, 574-574.	1.6	8
70	Abstract P6-18-24: Lapatinib-based therapies after pertuzumab and/or T-DM1 for HER2+ metastatic breast cancer patients. , 2019, , .		0
71	Abstract P6-17-05: Independent validation of a combined biomarker based on the PAM50 HER2-enriched subtype and ERBB2 mRNA levels following HER2 blockade without chemotherapy in the PerELISA phase II trial. , 2019, , .		0
72	Abstract P4-08-04: PD-L1 expression and prognosis in triple negative breast cancer (TNBC): An analysis of 265 patients (pts) treated with standard therapy for stage I-III disease. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
73	Abstract P6-17-08: Dynamics of tumor-infiltrating lymphocytes (TILs) during neoadjuvant dual HER2 blockade in HER2-positive (HER2+) breast cancer in the absence of chemotherapy. , 2019, , .		0
74	Abstract P6-17-07: Gene signatures and subtype changes during HER2 dual blockade in PAM50 HER2-enriched HER2-positive breast cancer. , 2019, , .		0
75	Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer. <i>Journal of Neuro-Oncology</i> , 2018, 138, 369-382.	2.9	19
76	Olaparib for the treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 519-530.	2.4	37
77	External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience. <i>Breast</i> , 2018, 37, 36-41.	2.2	31
78	First Prospective Multicenter Italian Study on the Impact of the 21â€™Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer. <i>Oncologist</i> , 2018, 23, 297-305.	3.7	8
79	A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure invasive lobular breast carcinoma (ILC). <i>Annals of Oncology</i> , 2018, 29, viii63.	1.2	0
80	Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology. <i>Oncologist</i> , 2018, 23, 1289-1299.	3.7	31
81	Oncological outcome of fat grafting for breast reconstruction after cancer. <i>Annals of Oncology</i> , 2018, 29, viii81.	1.2	0
82	Heterogeneity of triple negative breast cancer occurring in young women: an immunohistochemical analysis. <i>Breast</i> , 2018, 41, S19.	2.2	0
83	Immune characterization of breast cancer metastases: prognostic implications. <i>Breast Cancer Research</i> , 2018, 20, 62.	5.0	54
84	De-escalated treatment with trastuzumab-pertuzumab-letrozole in patients with HR+/HER2+ operable breast cancer with Ki67 response after 2 weeks letrozole: Final results of the PerELISA neoadjuvant study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 507-507.	1.6	6
85	Next-generation targeted sequencing (NGTS) investigating CDK4 as a prognostic driver in pure invasive lobular breast carcinoma (ILC): Preliminary results in early-stage patients (pts) stratified according to a validated clinico-pathological model.. <i>Journal of Clinical Oncology</i> , 2018, 36, 542-542.	1.6	1
86	Abstract P1-17-04: Clinical presentation and outcome of leptomeningeal metastasis in patients with breast cancer in relation to histology and tumor subtypes. , 2018, , .		0
87	Prognostic impact of proliferation for resected early stage â€™pureâ€™™ invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation. <i>Breast</i> , 2017, 35, 21-26.	2.2	16
88	Phase I study of lurbinectedin (PM01183) in combination with cisplatin (CDDP) with or without aprepitant in patients (pts) with advanced solid tumors. <i>European Journal of Cancer</i> , 2017, 72, S134.	2.8	2
89	Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2+ breast cancer: results from two prospective trials. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 295-302.	2.5	17
90	Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 766-772.	2.6	25

#	ARTICLE	IF	CITATIONS
91	Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all?. <i>Cancer Treatment Reviews</i> , 2017, 60, 100-108.	7.7	4
92	Beyond breast specificâ€”Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome. <i>Journal of Neuro-Oncology</i> , 2017, 131, 369-376.	2.9	8
93	Use of scalp-cooling device to prevent alopecia for breast cancer patients receiving chemotherapy: a single-institution prospective study. <i>Annals of Oncology</i> , 2017, 28, vi39.	1.2	0
94	External validation of modified breast graded prognostic assessment for breast cancer patients with brain metastases. <i>Annals of Oncology</i> , 2017, 28, v89.	1.2	0
95	A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in 739 patients (pts) affected by early stage pure Invasive Lobular breast Carcinoma (ILC). <i>Annals of Oncology</i> , 2017, 28, vi27.	1.2	1
96	CMET-29. HORMONE RECEPTORS STATUS: ASTRONG DETERMINANT OF THE KINETICS OF BRAIN METASTASES OCCURRENCE COMPARED WITH HER2 STATUS IN BREAST CANCER. <i>Neuro-Oncology</i> , 2017, 19, vi45-vi45.	1.2	0
97	ESR1, Ph-mTOR, CDK4/6 and PD-L1 expression as prognostic (and potentially druggable) drivers for pure invasive lobular breast carcinoma (ILC): Preliminary results of prognostic outliers according to a clinical-pathological model. <i>Annals of Oncology</i> , 2017, 28, v63.	1.2	0
98	Abstract P2-05-20: Tumor infiltrating lymphocytes in recurrent HER2+ and triple negative breast cancer: Prognostic value according to tumor phenotype. , 2017, , .		2
99	Abstract P1-12-06: Factors related to the prognosis of breast cancer patients after the development of brain metastases. , 2017, , .		0
100	First prospective multicenter Italian study on the impact of the 21-Gene Recurrence Score (RS) in adjuvant clinical decisions for ER+/HER2- early breast cancer (BC) patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, e12038-e12038.	1.6	0
101	A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in a multi-center series of resected early stage pure invasive lobular breast carcinoma (ILC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 539-539.	1.6	0
102	The immune system and hormone-receptor positive breast cancer: Is it really a dead end?. <i>Cancer Treatment Reviews</i> , 2016, 46, 9-19.	7.7	84
103	Lurbinectedin (PM01183) plus paclitaxel (P), recommended dose (RD) expansion results with or without the addition of bevacizumab (Bev) in patients (pts) with selected solid tumors. <i>Annals of Oncology</i> , 2016, 27, vi125.	1.2	3
104	Fat grafting for breast cancer patients: From basic science to clinical studies. <i>European Journal of Surgical Oncology</i> , 2016, 42, 1088-1102.	1.0	16
105	Cut-off analysis and prognostic relevance of Ki67 for resected early stage pure invasive lobular breast carcinoma (ILC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 544-544.	1.6	0
106	335 Lurbinectedin (PM01183) in combination with paclitaxel (P) in patients (pts) with advanced solid tumors. <i>European Journal of Cancer</i> , 2015, 51, S66.	2.8	0
107	316 Phase I study of lurbinectedin (PM01183) in combination with cisplatin (C) with or without aprepitant (Ap) in patients (pts) with advanced solid tumors. <i>European Journal of Cancer</i> , 2015, 51, S60.	2.8	0
108	A Case of Hodgkin Lymphoma in a Patient with a History of Bone Pain and an Initial Diagnosis of Chronic Osteomyelitis. <i>Tumori</i> , 2015, 101, e99-e102.	1.1	4



#	ARTICLE	IF	CITATIONS
109	BET inhibitors as potential anticancer agents. <i>Drugs of the Future</i> , 2015, 40, 0381.	0.1	2
110	Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab. <i>British Journal of Cancer</i> , 2014, 111, 25-32.	6.4	41
111	BRAF and KRAS mutations in liver-resected metastatic colorectal cancer (mCRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2014, 32, 476-476.	1.6	0